MONCTON, NB (OCTOBER 17, 2017) - Tieös Pharmaceuticals, a next-generation biotech company focused on cancer metabolic therapies, is pleased to announce that the company has been selected as a finalist in the 2017 BioInnovation Challenge being held in Halifax, Nova Scotia. This marks the first public presentation that Tieös has given, as it comes out of stealth mode.
The BioInnovation Challenge (BIC) was created for early stage life sciences companies with a clear intention to commercialize their products. The competition encompasses candidate companies across Nova Scotia, New Brunswick and Prince Edward Island and has provided support to the acceleration of life sciences companies in the Atlantic Canada region.
“We are honored to be finalists in the 2017 BioInnovation Challenge and look forward to further expanding our presence in Atlantic Canada,” said Arun Anand, CEO of Tieös Pharmaceuticals. “We also feel that this is an opportune time for Tieös to emerge from stealth mode and into the public scene as we move forward to an exciting phase in our drug development process.”
The 2017 BIC is presented by BioNova in partnership with the Atlantic Canada Opportunities Agency, BioNB, Emergence, Dalhousie University Industry Liaison and Innovation, Springboard Atlantic, Jennifer Cameron PR, JLT, Sandler Training and Grant Thornton.
“We were very impressed with the level of competition at this year’s BioInnovation Challenge. Tieös Pharmaceuticals presented extremely well and we expect to see great things from them in the years to come,” said Scott Moffitt, Managing Director with BioNova, the life sciences association of Nova Scotia and organizers of the BioInnovation Challenge.
The program is part of a regional collaboration between BioNova, BioNB and PEI BioAlliance, its sister organizations in NB and PEI. The program allows up and coming life sciences companies to compete in the challenge and kick start their success.
BioNova is the industry association leading the advancement of the life sciences sector in Nova Scotia. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities. BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations.
About Tieös Pharmaceuticals
Tieös Pharmaceuticals is a privately held pre-clinical stage biotech company, focused on developing novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells. Tieös’ lead compounds in development target multiple metabolic pathways simultaneously, while utilizing intelligent drug design elements to minimize drug resistance and collateral damage to healthy and vital cells. Founded in 2016, the company has offices in Ontario and New Brunswick, Canada. For more information, visit www.tieospharma.ca